New Guardant Reveal offering provides oncologists with tissue-free solution to monitor treatment response and detect early disease progression with unprecedented speed and sensitivity Reveal is ...
Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment Tissue-free approach addresses need for cancer patients who have no tissue ...
Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) ...
PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of ...
Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ...
Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer. Guardant, a biotechnology company, provides a blood ...
Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end. Ready ...
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s (NASDAQ:GH) Shield blood test for colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback